voltage-activated Ca 2ϩ channels and Ca 2ϩ release channels on sarcoplasmic reticulum within junctional membrane complexes. Although previous studies revealed a loss of junctional membrane complexes and embryonic lethality in germ-line junctophilin-2 (JPH2) knockout mice, it has remained unclear whether JPH2 plays an essential role in junctional membrane complex formation and the Ca 2ϩ -induced Ca 2ϩ release process in the heart. Our recent work demonstrated loss-of-function mutations in JPH2 in patients with hypertrophic cardiomyopathy. Methods and Results-To elucidate the role of JPH2 in the heart, we developed a novel approach to conditionally reduce JPH2 protein levels using RNA interference. Cardiac-specific JPH2 knockdown resulted in impaired cardiac contractility, which caused heart failure and increased mortality. JPH2 deficiency resulted in loss of excitationcontraction coupling gain, precipitated by a reduction in the number of junctional membrane complexes and increased variability in the plasmalemma-sarcoplasmic reticulum distance. Conclusions-Loss of JPH2 had profound effects on Ca 2ϩ release channel inactivation, suggesting a novel functional role for JPH2 in regulating intracellular Ca 2ϩ release channels in cardiac myocytes. Thus, our novel approach of cardiac-specific short hairpin RNA-mediated knockdown of junctophilin-2 has uncovered a critical role for junctophilin in intracellular Ca 2ϩ release in the heart. (Circulation. 2011;123:979-988.)
mechanism by which depolarization of the voltage-gated Ca 2ϩ channels (VGCCs) in the plasmalemma triggers a much greater release of Ca 2ϩ from the sarcoplasmic reticulum (SR) via type 2 ryanodine receptors (RyR2), a process known as Ca 2ϩ -induced Ca 2ϩ release (CICR). 1 This Ca 2ϩ release amplification depends on the organization of VGCC and RyR2 within junctional membrane complexes (JMCs), also known as calcium release units. 2 Disruption of JMC structure, as seen in heart failure, profoundly affects CICR and thus cardiac muscle contractility. 3 
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The molecular mechanisms involved in organizing Ca 2ϩ channels within the JMC remain poorly understood. One family of proteins, known as junctophilins (JPHs), has been proposed to provide a structural bridge between the plasmalemma and SR, thereby potentially ensuring approximation of VGCC and RyR2. 4 Junctophilin-2 (JPH2) is the major cardiac isoform among the 4 JPH isoforms, which are expressed within JMCs of all excitable cell types. 5 JPH proteins comprise 8 N-terminal "membrane occupation and recognition nexus" domains, a space-spanning ␣-helix, and a C-terminal transmembrane domain. The membrane occupation and recognition nexus domains mediate binding to the plasmalemma, and the hydrophobic transmembrane domain is anchored into the SR membrane. 6 The role of junctophilin in myocytes has remained unclear because of the lack of adequate animal models. Mice deficient in JPH1, the major skeletal muscle isoform, suffer from muscle abnormalities and perinatal death. 7 Genetic ablation of JPH2 results in embryonic lethality, most likely because of absence of cardiac contractility around embryonic day 10.5. 4 Therefore, the physiological role of JPH2 in the adult heart remains to be elucidated. In recent studies, we and another group have identified missense mutations in JPH2 in patients with hypertrophic cardiomyopathy. 8, 9 Moreover, decreased JPH2 expression was observed in a rat model of aortic stenosis and mouse models of hypertrophic and dilated cardiomyopathy. 10, 11 However, it remains to be determined whether downregulation of JPH2 is a mere response to heart failure or actually precipitates disease progression. Again, unraveling these questions has thus far been greatly hampered by the lack of a suitable animal model.
To circumvent the embryonic lethality associated with conventional genetic deletion of JPH2, we generated a novel transgenic mouse model that allows inducible cardiacspecific knockdown of JPH2 using RNA interference. We demonstrated that JPH2 deficiency is associated with the development of acute heart failure due to a loss of JMCs and reduced CICR. The CICR process was impaired because of reduced colocalization and functional coupling of VGCC and RyR2, without affecting expression levels. Moreover, loss of JPH2 impaired proper RyR2 inactivation, suggesting previously unrecognized roles for JPH2 in cardiac muscle and directly linking JPH2 deficiency to contractile dysfunction in failing hearts.
Methods
Please refer to the online-only Data Supplement for a more detailed Methods section.
Generation of Transgenic Mice
The generation of mice with cardiac-specific inducible short hairpin RNA (shRNA)-mediated knockdown of JPH2 is described in detail in the online-only Data Supplement.
Northern Blot and Real-Time Polymerase Chain Reaction
Detailed methods are provided in the expanded Methods section in the online-only Data Supplement.
Western Blotting and Coimmunoprecipitation
Western blotting and coimmunoprecipitation were performed as described in detail previously. 12
Immunohistochemistry and Histology
Detailed methods are provided in the online-only Data Supplement.
Transthoracic Echocardiography
Mice were anesthetized with the use of 1% to 2.0% isoflurane in 95% O 2 . Cardiac function was assessed with M-mode echocardiograms acquired with a VisualSonics VeVo 770 Imaging System (VisualSonics, Toronto, Ontario, Canada), as described. 13 
Electrophysiology and Ca 2؉ Imaging
Electron Microscopy
Computational Model
Statistical Analysis
Data are expressed as meanϮSEM. Statistical significance of differences between experimental groups was compared with Student t test and 1-way ANOVA with pairwise multiple comparisons performed with the Student-Newman-Keuls method as appropriate. If data were not normal according to the Shapiro-Wilk test, the Wilcoxon rank sum or Kruskal-Wallis test was used, as appropriate. A value of PϽ0.05 was considered statistically significant.
Results

Cardiac-Specific, Inducible JPH2 Knockdown With RNA Interference
To circumvent embryonic lethality associated with germ-line JPH2 knockout, we developed a novel approach for inducible cardiac-specific JPH2 knockdown. We first cloned 4 candidate shRNA oligonucleotides targeting different regions in mouse JPH2 and tested the knockdown efficiency in vitro ( Figure Ia 2) was used to generate a conditional JPH2 knockdown (shJPH2) mouse. shJPH2 mice harbor a transgene composed of the JPH2 shRNA sequence downstream of a U6 promoter, which is inactive because of the insertion of a loxP flanked neo cassette. 14 To ensure cardiac-specific shRNA expression, we crossed shJPH2 mice with ␣-myosin heavy chain (␣MHC)-MerCreMer (MCM) mice, which express a tamoxifeninducible mutant Cre recombinase under control of the cardiac-specific ␣MHC promoter. 15 Tamoxifen administration in double transgenic MCM-shJPH2 mice results in cardiac-specific excision of the neo cassette, which activates the U6 promoter and induces expression of JPH2 shRNA ( Figure 1A) .
Northern blot analysis confirmed expression of JPH2 shRNA exclusively in the hearts of tamoxifen-injected MCM-shJPH2 mice. Moreover, indicative of the cardiac specificity, there was no JPH2 shRNA expression in skeletal muscle of tamoxifen-injected MCM-shJPH2 mice ( Figure  1B ). Real-time polymerase chain reaction analysis revealed that JPH2 mRNA levels were significantly lower in hearts of tamoxifen-treated MCM-shJPH2 mice, whereas JPH1 mRNA levels were unaltered ( Figure 1C ). Western blot analysis of cardiac protein lysates demonstrated that knockdown of JPH2 mRNA resulted in a 60% reduction in JPH2 protein ( Figure 1B ). Because expression of double-stranded RNA might trigger a cellular interferon response with the potential to affect gene expression, 16 we measured mRNA levels of oligoadenylate synthase-1 (OAS1) and signal transducer and activator of transcription 1 (STAT1). Real-time polymerase chain reaction analysis demonstrated unaltered levels of OAS1 and STAT1 in tamoxifen-treated MCM-shJPH2 mice ( Figure Ic in the online-only Data Supplement). Whereas all provided data were obtained in mice from 1 transgenic line (line 38), we confirmed similar findings in a second independent shJPH2 transgenic mouse line (line 21) in which JPH2 was reduced by 30% after tamoxifen administration (data not shown). These data show that we successfully created a novel shRNA-mediated approach to selectively reduce JPH2 protein levels in the adult murine heart.
Downregulation of JPH2 Leads to Acute Heart Failure
JPH2 knockdown in MCM-shJPH2 mice caused a significantly reduced survival rate compared with MCM mice ( Figure 1D ). Within 1 week after tamoxifen injections, mortality was 40% among MCM-shJPH2 mice compared with 0% among MCM mice (Pϭ0.004). Histological analysis of surviving mice revealed cardiac dilatation in MCM-shJPH2 mice ( Figure 1E ). Transthoracic echocardiography revealed significantly decreased ejection fractions in MCM-shJPH2 mice (36.72Ϯ 4.25%) compared with MCM controls (51.97Ϯ2.15%; PϽ0.01) ( Figure 1F ; Table in the online-only Data Supplement). Furthermore, end-systolic diameter and end-diastolic diameter were both significantly larger in MCM-shJPH2 (3.89Ϯ0.16 and 4.80Ϯ0.07 mm, respectively) compared with MCM control mice (3.19Ϯ0.07 and 4.35Ϯ0.06 mm; PϽ0.001) ( Figure 1G and 1H). Similar findings were obtained in MCM-shJPH2 mice from line 21 (Table in the 
Loss of EC Coupling Gain in JPH2 Knockdown Mice
We next determined the effects of JPH2 knockdown on EC coupling by simultaneously measuring VGCC Ca 2ϩ influx and 
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RyR2 Ca 2ϩ release. Whereas Ca 2ϩ influx through VGCC was unaffected by loss of JPH2, Ca 2ϩ release from the SR (ie, Ca 2ϩ transients) was significantly smaller in tamoxifen-treated MCM-shJPH2 mice (Figure 2A ). As a result, the gain of EC coupling was reduced by Ͼ50% after JPH2 knockdown (MCM-shJPH2: 0.11Ϯ0.02 versus MCM: 0.29Ϯ0.06; PϽ0.05; Figure 2B ). Further analysis revealed that neither inactivation kinetics (MCM: 35.79Ϯ2.53 ms versus MCM-shJPH2: 31.37Ϯ2.18 ms; Pϭ0. 19 ) nor current-voltage relationship of VGCC was affected by loss of JPH2 ( Figure 2C and 2D). The total amount of Ca 2ϩ entering the cell via VGCC was also comparable between MCM-shJPH2 (4.35Ϯ0.21 pA/pF) and MCM mice (4.25Ϯ0.27 pA/pF; PϭNS; Figure 2E ). In addition to the Ca 2ϩ influx trigger, the amount of SR Ca 2ϩ release also depends on SR Ca 2ϩ load and activity of RyR2 channels. Therefore, we assessed the amount of Ca 2ϩ stored in the SR after steady state pacing at 1 Hz ( Figure 2F ). Consistent with EC coupling experiments (Figure 2A ), the amplitude of pacing-evoked Ca 2ϩ transients was decreased in MCM-shJPH2 mice (1.91Ϯ0.06 F/F0) compared with MCM controls (2.30Ϯ0.10; PϽ0.01; Figure 2G ). SR Ca 2ϩ content, measured by a caffeine dump protocol, was significantly decreased in MCM-shJPH2 mice (2.92Ϯ0.25 F/F0 versus 4.10Ϯ0.33 F/F0; PϽ0.01; Figure 2H) . Surprisingly, however, we observed that the relative amount of SR Ca 2ϩ released via RyR2 normalized to SR Ca 2ϩ content (ie, fractional release) was increased when JPH2 was downregulated ( Figure 2I ). Because the Ca 2ϩ decay curves in the presence of caffeine appeared shallower in MCM-shJPH2 mice compared with MCM controls, we further analyzed Na ϩ -Ca 2ϩ exchange activity. We found that values were significantly decreased after JPH2 knockdown (ϭ2.70Ϯ0.23 for MCM versus 5.11Ϯ0.61 for MCM-shJPH2 mice, respectively; PϽ0.01). Combined, these data suggest that 1 consequence of JPH2 deficiency is reduced VGCC-RyR2 coupling leading to reduced cardiomyocyte contractility due to a novel role of JPH2 in directly regulating RyR2 activity.
JPH2 Knockdown Disrupts JMC Organization
To ascertain the effects of JPH2 deficiency on the structure of JMCs, we first examined colocalization of VGCC and RyR2 in ventricular myocytes from MCM-shJPH2 mice. Immunofluorescent imaging indicated that both types of Ca 2ϩ channels were distributed in similar striated patterns ( Figure 3A through 3D). However, colocalization between the 2 channels was significantly decreased after JPH2 knockdown, and this was not due to a difference in protein levels ( Figure 3E and 3F). Thus, loss of JPH2 results in defective colocalization of VGCC and RyR2 Ca 2ϩ channels within the JMC.
We therefore examined the structure of transverse (T)tubules using di-8-ANEPPS staining. A significant disruption of normal T-tubular structure was apparent in cardiomyocytes from tamoxifen-treated MCM-shJPH2 mice ( Figure 4A and Figure II in the online-only Data Supplement). These alterations in T-tubular structure did not affect membrane capacitance (average membrane capacitanceϭ184.6Ϯ22.6 pF for MCM versus 165.8Ϯ22.6 pF for MCM-shJPH2 mice, respectively; Pϭ0.27). Transmission electron microscopy was used to investigate ultrastructural changes in the JMCs ( Figure  4B ). Cardiomyocytes from MCM-shJPH2 mice had 40% fewer JMCs (0.36Ϯ0.04 JMCs per sarcomere) than MCM control mice (0.59Ϯ0.01; Figure 4C ). Furthermore, the remaining JMCs were irregular in terms of their structure. Whereas the average distance between the T-tubular membrane and SR membrane was similar (12.45Ϯ0.52 nm in MCM-shJPH2 versus 12.30Ϯ0.26 nm in MCM), the gap between the 2 membranes within a single JMC (intradyad width) was more variable in MCM-shJPH2 mice (variance 1.96 nm 2 ) than in MCM controls (variance 1.21 nm 2 ; PϽ0.01; Figure 4D ). In addition, dyad width among different JMCs (interdyad width) was significantly more variable in MCM-shJPH2 cardiomyocytes (variance 0.26 nm 2 ) compared with MCM controls (variance 1.07 nm 2 ; Figure 4E ). Therefore, acute loss of JPH2 leads to altered morphology and loss of JMCs.
JPH2 Stabilizes the Ryanodine Receptor Ca 2؉ Release Channel
The reduction in JMC number and disruption of VGCC/RyR2 colocalization could account for the attenuated EC coupling gain ( Figure 2 ). However, structural uncoupling of VGCC and RyR2 would theoretically cause reduced RyR2 triggering, leading to increased SR Ca 2ϩ . Because we observed the exact opposite, a reduction in SR Ca 2ϩ content ( Figure 2F and 2H), we decided to assess RyR2 channel behavior during cellular diastole in cardiomyocytes from MCM-shJPH2 mice ( Figure 5A and 5B ). Ventricular myocytes of MCM-shJPH2 mice exhibited an increase in cell-wide spontaneous Ca 2ϩ release events after a 1-Hz pacing train compared with MCM mice (Figure 5A and 5C ). Next, we used confocal line scan imaging to visualize Ca 2ϩ sparks in isolated cardiomyocytes ( Figure 5B ). Knockdown of JPH2 in MCM-shJPH2 mice led to a significantly higher Ca 2ϩ spark frequency ( Figure 5B and 5D). Taken together, our data indicate that loss of JPH2 leads to increased diastolic Ca 2ϩ leak via RyR2 channels. Moreover, this suggests that JPH2 is an important RyR2 regulator besides its structural role in the JMC. Immunoprecipitation of RyR2 from mouse heart tissue revealed that JPH2 binds to RyR2, further supporting a novel role of JPH2 in directly regulating RyR2 ( Figure 5F ). Thus, our data suggest that JPH2 is required for proper inactivation of RyR2 and that loss of JPH2 can cause diastolic Ca 2ϩ leaks.
Effect of JMC Alterations on EC Coupling Gain in a Computational Model
Our experimental data in MCM-shJPH2 mice revealed that acute loss of JPH2 leads to a reduced number of JMCs and an increased variability in the distance between the plasmalemmal and SR membranes. In our in vivo model, however, it is not possible to distinguish the individual contributions of these alterations to EC coupling gain, which was severely impaired after JPH2 knockdown. Therefore, we used a mathematical model to quantitatively probe the effects of Figure 6A ). The Luo-Rudy myocyte simulation model was used, with a modified Ca 2ϩ cycling process represented by up to 10 000 discrete Ca 2ϩ release units. 17 With the use of the exact values for JMC number and interdyad and intradyad width variance obtained in the tamoxifen-treated MCM and MCM-shJPH2 mice, the model predicts a 64% drop in EC coupling gain, which is very similar to our in vivo measurements (60.0Ϯ5.7%; Figure 6B ). First, we simulated the effect of reducing the number of JMCs (or dyads) ( Figure 6C ). Our data reveal that a reduction in the number of dyads leads to a reduction in EC coupling gain according to a nearly linear relationship. Subsequently, the effects of changing interdyad or intradyad width variability were also simulated. In both cases, experimentally observed changes in interdyad or intradyad width variability (marked in the Figure) were predicted to decrease EC coupling gain ( Figure 6D and 6E) . Finally, we compared the relative contribution of each of these changes in the JMC to the loss of EC coupling gain ( Figure 6F ). The reduction in dyad number was the main contributor, followed by the increase in intradyad variability and interdyad variability. Combined, these changes account for the severe loss of EC coupling gain, consistent with decreased cardiac contractility observed after JPH2 knockdown.
Rescue of JPH2 Knockdown Phenotype by Overexpression of JPH2
Although shRNA-mediated knockdown of JPH2 expression represents a powerful tool to study the role of JPH2 in the heart, it is theoretically possible that the observed phenotype was due to nonspecific side effects of transgene integration or off-target effects of shRNA. Although this seemed less likely without an interferon response and normal mRNA levels of the lesser cardiac JPH isoform (JPH1), we performed a series of rescue experiments to further prove the specificity of shRNA-mediated JPH2 knockdown effects. We intercrossed the MCM-shJPH2 mice with transgenic mice overexpressing JPH2 in the heart (OE). Western blot analysis of cardiac lysates revealed supranormal JPH2 levels in tamoxifentreated MCM-shJPH2-OE triple transgenic mice ( Figure 7A ). Echocardiographic analysis revealed that fractional shortening and cardiac dimensions were similar in MCM-shJPH2-OE and MCM mice, suggesting that JPH2 overexpression in hearts of JPH2 knockdown mice rescued cardiac dysfunction ( Figure 7B and Table in the online-only Data Supplement). Furthermore, electron microscopy analysis showed complete rescue of ultrastructural abnormalities, as did confocal imaging of Ca 2ϩ transient amplitudes ( Figure 7C  and 7D) . Thus, the cardiac phenotype in MCM-shJPH2 mice is specifically caused by shRNA-mediated knockdown of JPH2 in the heart.
Discussion
Proper conversion of plasmalemmal depolarization into release of intracellular Ca 2ϩ from the SR is a prerequisite for myocyte contractility. 18 This fundamental process known as CICR takes place within specialized subcellular domains known as JMCs. JMCs are found in all excitable cell types and are believed to be necessary to provide a structural and functional coupling between the plasma membrane and intracellular Ca 2ϩ storage organelles such as the SR. In heart failure, the reduced CICR and disorganization of JMC are believed to contribute to contractile dysfunction, although the molecular mechanisms remain poorly understood.
After the initial discovery of the JPH family, it was postulated that this class of proteins provides a structural bridge that anchors the SR membrane to the plasmalemma within JMCs. Previous studies in germ-line JPH2 knockout mice revealed embryonic lethality at E10.5 due to weakened contractility and heart failure. 4 Although embryonic JPH2deficient mice exhibited defective calcium release units, whether this was directly caused by the absence of JPH2 has remained controversial because other knockout mouse models, including triadin-deficient mice, display similar subcellular defects. 19 To overcome these limitations, we developed a novel shRNA-based interference approach to induce acute knockdown of JPH2 expression levels exclusively in adult mice cardiac myocytes (MCM-shJPH2 mice). Our findings revealed reproducible JPH2 knockdown after tamoxifen administration in 2 independent transgenic MCM-shJPH2 lines. It is important to highlight that conventional tissue-specific gene knockout only produces heterozygous (50% knockout) and homozygous (100% knockout) genotypes. In contrast, our shRNA-based model allowed us to study a wide range of knockdown percentages in MCM-shJPH2 mice. Thus, our new approach to inducible and cardiac-specific gene knockdown enabled us to determine the specific role of JPH2 in the maintenance of cardiac structure and function. Specificity of the model was confirmed by demonstrating that transgenic overexpression of JPH2 in MCM-shJPH2 knockdown mice prevented loss of JPH2 and negated the development of cardiac and cellular phenotypes linked to JPH2 deficiency.
Our findings suggest that loss of JPH2 is directly responsible for impaired cardiac contractility, one of the hallmarks of congestive heart failure. Loss of JPH2 expression in MCM-shJPH2 mice caused development of acute contractile failure in the absence of myocardial remodeling or alterations in expression levels of other Ca 2ϩ handling proteins, suggesting that JPH2 deficiency impaired EC coupling within the JMC. Furthermore, our data indicate that loss of cardiac JPH2, as observed in animal models for heart failure, 10, 11 is not a compensatory response during heart disease development but actually plays a causal role in the disease progression. The finding that genetic mutations in JPH2 cause hypertrophic cardiomyopathy and heart failure also implies a causal link between JPH2 defects and heart disease. 8, 9 Previous studies in animals with congestive heart failure revealed reduced EC coupling due to an inability of VGCC to trigger sufficient SR Ca 2ϩ release. 20 Our findings in cardiomyocytes isolated from MCM-shJPH2 mice suggest that loss of JPH2 expression is directly responsible for defective CICR. Furthermore, JPH2 knockdown in adult cardiomyocytes increased variability in the distance between the SR and plasma membrane within a single JMC and among populations of JMCs. These data suggest that the remaining JPH2 proteins are sufficient to keep both membranes together as JMCs but that the fidelity of JMC morphology is significantly affected by the loss of JPH2. 
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The T-tubular system permits the formation of larger numbers of JMCs within cardiomyocytes. T-tubule remodeling has been demonstrated in rats with pressure overloadinduced heart failure 21 and patients with congestive heart failure. 22 In a recent study, heart failure development was correlated with progressive defects in T-tubule organization and a decline in JPH2 expression levels. 21 Our findings provide, for the first time, a causal link between acute loss of JPH2 in MCM-shJPH2 mice and a reduction in the total number of JMCs and loss of T-tubules in ventricular myocytes. Normalization of the number of JMCs per sarcomere in MCM-shJPH2 mice intercrossed with JPH2 OE mice further underscores the specific role of JPH2 in maintaining JMC structure. Thus, our data demonstrate that JPH2 is an essential component of the JMC and that loss of JPH2 leads to disappearance of JMCs within affected cardiomyocytes.
Our studies in cardiomyocytes isolated from JPH2 knockdown mice revealed evidence for spontaneous Ca 2ϩ releases from the SR ( Figure 5 ). On the basis of findings in embryonic JPH2-deficient mice, it has been suggested previously that impaired coupling between VGCC and RyR2 might lead to impaired emptying of the SR, resulting in overload-induced diastolic SR Ca 2ϩ release. 4 However, our findings clearly revealed a reduction in overall SR Ca 2ϩ content, which argues against this model ( Figure 2H ). Because cardiac RyR2 expression was unaltered after JPH2 knockdown, it is more likely that the loss of JPH2 impairs the ability of RyR2 to remain closed during diastole. The finding that JPH2 can be coimmunoprecipitated with the use of anti-RyR2 antibody is also consistent with direct binding and regulation of RyR2 by JPH2. In fact, defective RyR2 regulation contributes to abnormal Ca 2ϩ handling in failing hearts. 23 Thus, our data implicate JPH2 as a new allosteric regulator of RyR2 function and suggest that JPH2 downregulation can directly impair RyR2 Ca 2ϩ release in failing hearts.
Moreover, we found that Ca 2ϩ -dependent inactivation of VGCC was not altered in MCM-shJPH2 mice, which might be surprising given that the systolic SR Ca 2ϩ transient was reduced (Figure 2 ). However, it is possible that diastolic SR Ca 2ϩ leak due to increased RyR2 leak might elevate diastolic Ca 2ϩ levels, thereby normalizing Ca 2ϩ -dependent inactivation in MCM-shJPH2 mice. Therefore, it would be interesting to directly measure diastolic Ca 2ϩ concentrations in future experiments. Finally, we found that Na ϩ -Ca 2ϩ exchange activity was reduced in myocytes from MCM-shJPH2 mice despite unaltered global expression levels. These results suggest that JPH2 might be required for proper subcellular targeting of Na ϩ -Ca 2ϩ exchange, but direct evidence for this is currently not available.
In conclusion, we have developed a novel approach to conditionally reduce JPH2 protein levels using RNA interference. Our studies uncovered the physiological roles of JPH2 in cardiac myocytes and implicate JPH2 as an important factor involved in the loss of cardiac contractility in heart failure, a key feature of this prevalent disease. In addition to determining the spacing between the plasmalemma and SR membrane, JPH2 is also required for the structural integrity of JMCs in myocytes. Computational analysis provided further quantitative insights into the relative importance of each of these subcellular defects related to impaired EC coupling. Moreover, we found that JPH2 associates with and facilitates RyR2 inactivation, thereby preventing diastolic SR Ca 2ϩ leak. This dual functional role for JPH2 in cardiomyocytes may have implications for the development of new therapeutic strategies for heart failure. 
